IBD Therapy Complexity Drives Administrative Volume
Inflammatory bowel disease — Crohn's disease and ulcerative colitis — has been transformed by biologic therapy over the past two decades. Anti-TNF agents, integrin inhibitors, IL-12/23 inhibitors, and JAK inhibitors have dramatically improved outcomes for patients with moderate-to-severe disease, but each of these therapies brings an administrative footprint that scales with the patient panel.
The Crohn's & Colitis Foundation's 2025 Patient Access Survey found that 61 percent of patients on biologic therapy experienced at least one insurance-related delay in the prior 12 months, with prior authorization denials, step therapy requirements, and specialty pharmacy delays as the leading causes. For IBD clinics managing panels of hundreds of biologic patients, the administrative workload of managing these access barriers is substantial.
Virtual assistants with IBD clinic training are stepping into this workflow, managing the recurring authorization, scheduling, and billing cycles that biologic therapy requires — and doing so with the systematic consistency that human staff cannot always maintain under high volume.
Infusion Scheduling: A Recurring Coordination Challenge
Patients receiving intravenous biologic infusions — such as infliximab or vedolizumab — require infusion appointments that must be scheduled, confirmed, and coordinated with infusion center availability on a recurring schedule, typically every four to eight weeks depending on the agent and the patient's treatment phase. Induction regimens require infusions at weeks zero, two, and six, then transition to maintenance — a schedule that requires careful tracking.
Each infusion appointment requires verifying that the prior authorization is current, confirming the medication has been ordered and will be available at the infusion site, and ensuring the patient has confirmed their appointment. A missed infusion due to a lapsed authorization or scheduling breakdown can trigger a disease flare, a costly complication both clinically and economically.
A 2025 analysis in Inflammatory Bowel Diseases journal found that infusion schedule gaps of more than two weeks beyond the intended interval were associated with a 34 percent increase in the likelihood of disease flare requiring emergency care or hospitalization. The administrative infrastructure around infusion scheduling is, in effect, a clinical safety system.
Virtual assistants manage the infusion scheduling cycle end-to-end: confirming authorization currency before scheduling, booking appointments with infusion centers, sending patient reminders, and flagging any authorization lapses before they interrupt therapy.
Prior Authorization: The Biologic Therapy Maze
Biologic prior authorizations for IBD are among the most complex in outpatient medicine. Insurers require documentation of failed conventional therapy, current disease activity scores in some cases, and prior authorization of specific biologics before others — the step therapy requirements that force patients through a sequence of treatments regardless of physician preference. Each authorization covers a defined period and must be renewed, typically annually, with updated documentation of response and continued medical necessity.
The specialty pharmacy prior authorization layer adds another dimension: infused biologics must be authorized for purchase by the infusion center or hospital, and self-injectable biologics require specialty pharmacy authorization separate from the medical benefit. Managing both layers simultaneously requires staff with precise knowledge of each insurer's requirements.
Virtual assistants trained in IBD authorization workflows manage submission, renewal tracking, step therapy exception requests, and appeals. For practices with 100 or more patients on biologic therapy, a dedicated VA focusing on prior auth management can prevent dozens of therapy interruptions per year.
Specialty Pharmacy Coordination and Billing
Self-injectable biologic therapies — subcutaneous adalimumab, ustekinumab, and others — are typically dispensed through specialty pharmacies rather than retail channels, adding coordination requirements that are distinct from infused therapy. Virtual assistants can manage specialty pharmacy enrollment, prior authorization submission to pharmacy benefit managers, and follow-up when specialty pharmacy orders are delayed or denied.
On the billing side, infused biologics billed under the medical benefit require accurate J-code application with precise units — billing a single unit error on an infliximab claim can result in significant underpayment. Virtual assistants with specialty billing training review charges for unit accuracy, manage denial resolution, and track outstanding claims systematically.
For IBD practices seeking comprehensive administrative support without expanding full-time headcount, Stealth Agents provides virtual assistants trained in specialty GI and biologic therapy workflows who can integrate with EHR and infusion center scheduling platforms.
Sources
- Crohn's & Colitis Foundation, 2025 Patient Access and Insurance Barriers Survey, crohnscolitisfoundation.org
- Inflammatory Bowel Diseases Journal, "Infusion Interval Gaps and Clinical Outcomes in Biologic-Treated IBD," 2025
- National Infusion Center Association, 2025 Outpatient Infusion Therapy Access Report, nicainfusion.org
- Medical Group Management Association, 2025 Specialty Prior Authorization Burden in GI Practices, mgma.com